OJOph  Vol.2 No.4 , November 2012
Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma
Author(s) Italo Giuffre*
ABSTRACT
Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by na?ve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age- and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.

Cite this paper
I. Giuffre, "Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma," Open Journal of Ophthalmology, Vol. 2 No. 4, 2012, pp. 122-126. doi: 10.4236/ojoph.2012.24027.
References
[1]   S. D. Vold, R. M. Evans, R. H. Stewart et al., “A One-Week Comfort Study of BID-Dosed Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension Fixed Combination Compared to BID-Dosed Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension,” Journal of Ocular Pharmacology and Therapeutics, Vol. 24, No. 6, 2008, pp. 601-605. doi:10.1089/jop.2008.0030

[2]   U. Thelen, P. Bucholz and F. Kimmich, “Treatment of Patients with Primary Open-Angle Glaucoma with a Fixed Combination of Brimonidine 0.2%/Timolol 0.5%: Multicenter, Open-Label, Observational Study in Germany,” Current Medical Research and Opinion, Vol. 25, No. 4, 2009, pp. 1003-1009. doi:10.1185/03007990902805916

[3]   A. G. Konstas, I. E. Katsimpris, K. Kaltsos, et al., “Twenty-Four Hour Efficacy of the Brimonidine/Timolol Fixed Combination versus Therapy with the Unfixed Components,” Eye, Vol. 22, No. 11, 2008, pp. 1391-1397. doi:10.1038/sj.eye.6702906

[4]   M. B. Sherwood, E. R. Craven, C. Chou et al., “Twice-Daily 0.2% Brimonidine-0.5% Timolol Fixed Combination Therapy vs Monotherapy with Timolol or Brimonidine in Patients with Glaucoma or Ocular Hypertension,” Archives of Ophthalmology, Vol. 124, No. 9, 2006, pp. 1230-1238. doi:10.1001/archopht.124.9.1230

[5]   F. J. Goni, “For the Brimonidine/Timolol Fixed Combination Study Group: 12 Week Study Comparing the Fixed Combination of Brimonidine and Timolol with Concomitant Use of the Individual Components in Patients with Glaucoma and Ocular Hypertension,” Eurpean Journal of Ophthalmology, Vol. 15, No. 5, 2005, pp. 581-590.

[6]   G. L. Spaeth, P. Bernstein, J. Caprioli and R. M. Schiffman, “Control of Intraocular Pressure and Fluctuation with Fixed-Combination Brimonidine-Timolol verus Brimonidine or Timolol Monotherapy,” American Journal of Ophthalmology, Vol. 151, No. 1, 2011, pp. 93-99. doi:10.1016/j.ajo.2010.07.024

[7]   S. W. Cho, J. M. Kim, K. H. Park and C. Y. Choi, “Effects of Brimonidine 0.2%-Timolol 0.5% Fixed Combination Therapy for Glaucoma,” Japanese Journal of Ophthalmology, Vol. 54, No. 5, 2010, pp. 407-413. doi:10.1007/s10384-010-0855-4

[8]   A. Hommer, P. Sperl, H. Resch, et al., “A Double-Masked Randomized Crossover Study Comparing the Effect of Latanoprost/Timolol and Brimonidine/Timolol Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension,” Journal of Ocular Pharmacology and Therapeutics, July 9, 2012. doi:10.1089/jop.2011.0165

[9]   L. J. Katz, S. H. Rauchman, A. J. Cottingham, et al., “Fixed-Combination Brimonidine-Timolol versus Latanoprost in Glaucoma and Ocular Hypertension: A 12-Week, Randomized, Comparison Study,” Current Medical Research and Opinion, Vol. 28, No. 5, 2012, pp. 781-788. doi:10.1185/03007995.2012.681036

[10]   B. Pajic, B. Pajic-Eggspuehler and I. O. Hafliger, “Comparison of the Effects of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations upon Intraocular Pressure and Progression of Visual Field Damage in Primary Open-Angle Glaucoma,” Current Medical Research and Opinion, Vol. 26, No. 9, 2010, pp. 2213-2219. doi:10.1185/03007995.2010.508702

[11]   B. Cvenkel, J. A. Stewart, L. A. Nelson and W. C. Stewart, “Dorzolamide/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension,” Current Eyes Research, Vol. 33, No. 2, 2008, pp. 163-168. doi:10.1080/02713680701832480

[12]   T. Rolle, F. Tofani, B. Brogliatti and F. M. Grignolo, “The Effects of Dorzolamide 2% and Dorzolamide/Timolol Fixed Combination on Retinal and Optic Nerve Head Blood Flow in Primary Open-Angle Glaucoma Patients,” Eye, Vol. 22, No. 9, 2008, pp. 1172-1179. doi:10.1038/sj.eye.6703071

[13]   E. D. Sharpe, R. D. Williams, J. A. Stewart, et al., “A Comparison of Dorzolamide/Timolol Fixed Combination versus Bimatoprost in Patients with Open-Angle Glaucoma Who Are Poorly Controlled on Latanoprost,” Journal of Ocular Pharmacology and Therapeutics, Vol. 24, No. 4, 2008, pp. 408-413. doi:10.1089/jop.2008.0003

[14]   J. Mulaney, S. Sonty, A. Ahmad, et al., “Comparison of Daytime Efficacy and Safety of Dorzolamide/Timolol Maleate Fixed Combination versus Latanoprost,” European Journal of Ophthalmology, Vol. 18, No. 4, 2008, pp. 556-562.

[15]   L. Quaranta. S. Miglior, I. Floriani, et al., “Effects of the Timolol-Dorzolamide Fixed Combination and Latanoprost on Circadian Diastolic Ocular Perfusion Pressure in Glaucoma,” IOVS, Vol. 49, No. 10, 2008, pp. 4226-4231.

[16]   A. G. Konstas, L. Quaranta, D. B. Yan, et al., “Twenty-Four Hour Efficacy with the Dorzolamide/Timolol-Fixed Combination Compared with the Brimonidine/Ti-molol-Fixed Combination in Primary Open-Angle Glaucoma,” Eye, Vol. 26, No. 1, 2011, pp. 80-87.

[17]   M. H. Eren, H. Gungel, C. Altan, et al., “Comparison of Dorzola-mide/Timolol and Latanoprost/Timolol Fixed Combinations on Diurnal Intraocular Pressure Control in Primary Open-Angle Glaucoma,” Journal of Ocular Pharmacology and Therapeutics, Vol. 28, No. 4, 2012, pp. 381- 386. doi:10.1089/jop.2011.0105

[18]   A. G. Konstas, L. Quaranta, D. B. Yan et al., “Twenty-Four Hour Efficacy with the DOR-ZOLAMIDE/ Timolol-Fixed Combination Compared with the Brimonidine/Timolol-Fixed Combination in Primary Open-Angle Glaucoma,” Eye, Vol. 26, No. 1, 2012, pp. 80-87. doi:10.1038/eye.2011.239

[19]   G. Shemesh, E. Moisseiev and M. S. Lazar, “Intraocular Pressure Reduction of Fixed Combination Timolol maleate 0.5% and Dorzolamide 2% (Cosopt) Administered Three Times a Day,” Journal of Clinical Ophthalmology, Vol. 6, 2012, pp. 283-287.

[20]   G. Hollo, B. Bozkurt and M. Irkec, “Brinzolamide/Timolol Fixed Combi-nation: A New Ocular Suspension for the Treatment of Open-Angle Glaucoma and Ocular Hy- pertension,” Expert Opinion on Pharmacotherapy, Vol. 10, No. 12, 2009, pp. 2015-2024. doi:10.1517/14656560903124388

[21]   G. L. Manni, P. Denis, P. Chew, et al., “The Safety and Efficacy of Brinzolamide 1%/ Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension,” Journal of Glaucoma, Vol. 18, No. 4, 2009, pp. 293-300. doi:10.1097/IJG.0b013e31818fb434

[22]   M. F. Syed and E. K. Loucks, “Update and Optimal Use of a Brinzolamide-Timolol Fixed Combination in Open-Angle Glaucoma and Ocular Hypertension,” Journal of Clinical Ophthalmology, Vol. 5, 2011, pp. 1291-1296. doi:10.2147/OPTH.S13786

[23]   M. Nebbioso, M. Evangelista, A. Librando, D. di Blasio and N. Pescosolido, “Fixed Topical Combinations in Glaucomatous Patients and Ocular Discomfort,” Expert Opinion on Pharmacotherapy, Vol. 13, No. 13, 2012, pp. 1289-1295. doi:10.1517/14656566.2012.705830

[24]   A. Katsanos, A. I. Dastiridou, M. Fanariotis et al., “Bima- toprost and Bimatoprost/Timolol Fixed Combination in Patients with Open-Angle Glaucoma and Ocular Hyper-Tension,” Journal of Ocular Pharmacology and Therapeutics, Vol. 27, No. 1, 2011, pp. 67-71. doi:10.1089/jop.2010.0090

[25]   G. Brief, T. Lammich, E. Nagel, et al., “Fixed Combination of Bimatoprost and Timolol in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension With Inadequate IOP Adjustment,” Journal of Clinical Ophthalmology, Vol. 5, No. 4, 2010, pp. 1125-1129.

[26]   R. Jothi, A. M. Ismail, R. Senthamarai and S. Pal, “A Comparative Study on the Efficacy, Safety, and Cost-Effectiveness of Bimatoprost/Timolol and Dorzolamide/Timolol Combinations in Glaucoma Patients,” Indian Journal of Pharmacology, Vol. 42, No. 6, 2010, pp. 362-365. doi:10.4103/0253-7613.71917

[27]   M. Centofanti, F. Oddone, S. Gandolfi, et al., “Comparison of Travoprost and Bimato-prost Plus Timolol Fixed Combinations in Open-Angle Glaucoma Patients Previously Treated with Latanoprost Plus Timolol Fixed Combination,” American Journal of Ophthamology, Vol. 150, No. 4, 2010, pp. 575-580. doi:10.1016/j.ajo.2010.05.003

[28]   A. G. P. Konstas, S. Tsironi, A. N. Vakalis, et al., “Intraocular Pressure Control Over 24 Hours Using Travoprost and Timolol Fixed Combination Administered in the Morning or Evening in Primary Open-Angle and Exfoliative Glaucoma,” Acta Ophthalmologyl, Vol. 87, No. 1, 2009, pp. 71-76. doi:10.1111/j.1755-3768.2007.01145.x

[29]   A. G. Konstas, D. G. Mikropoulos, T. A. Embeslidis, et al., “24-H Intraocular Pressure Control with Evening Dosed Travoprost/Timolol, Compared with Latanoprost/Timolol, Fixed Combinations in Exfoliative Glaucoma,” Eye, Vol. 24, No. 10, 2010, pp. 1606-1613. doi:10.1038/eye.2010.100

[30]   F. Aptel, M. Cucherat and P. Denis, “Efficacy and Tolerability of Prostaglandin-Timolol Fixed Combinations: A Meta-Analysis of Randomized Clinical Trials,” European Journal of Ophthalmology, Vol. 22, No. 1, 2012, pp. 5-18. doi:10.5301/ejo.5000009

[31]   M. Herceg and R. Noecker, “Travoprost/Timolol Fixed Combination,” Expert Opinion on Pharmacotherapy, Vol. 9, No. 6, 2008, pp. 1059-1065. doi:10.1517/14656566.9.6.1059

[32]   P. Fogagnolo and L. Rossetti, “Medical Treatment of Glaucoma: Present and Future,” Expert Opinion on Investigational Drugs, Informa Healthcare, Vol. 20, No. 7, 2011, pp. 947-959.

[33]   J. P. Rigollet, J. A. Ondategui, A. Pasto and L. Lop, “Randomized Trial Comparing Three Fixed Combinations of Prostagland-ins/Prostamide with Timolol Maleate,” Journal of Clinical Ophthalmology, Vol. 5, 2011, pp. 187-191.

[34]   A. Hommer, “Role of Fixed Combinations in the Management of Open-Angle Glaucoma,” Expert Reviews of Pharmacoecon Outcomes Research, Vol. 11, No. 1, 2011, pp. 91-99.doi:10.1586/erp.10.83

[35]   P. Denis, “Travoprost/Timolol Fixed Combination in the Management of Open-Angle Glaucoma: A Clinical Review,” Expert Opinion on Pharmacotherapy, Vol. 12, No. 3, 2011, pp. 463-471. doi:10.1517/14656566.2011.551007

[36]   M. L. Scherzer, I. Liehneova, F. J. M. Negrete and D. Schnober, “Combinazione Fissa Travoprost 0.004%/ Timololo 0.5% Nei Pazienti in Transizione Terapeutica da Bimatoprost 0.03%/Timololo 0.5% Combinazione Fissa o Non Fissa,” Advances in Therapy, Vol. 28, No. 8, 2011, pp. 661-670. doi:10.1007/s12325-011-0043-z

[37]   A. G. Konstas, L. Quaranta and T. Realini, “Overview of the BAK-Free Travoprost/Timolol BAK-Free Fixed Combination,” Expert Opinion on Pharmacotherapy, Vol. 13, No. 5, 2012, pp. 757-766. doi:10.1517/14656566.2012.662485

[38]   V. P. Costa, H. Moreira, M. D. Paolera and M. R. de Moraes- Silva, “Efficacy and Safety of Travoprost 0.004%/ Timolol 0.5% Fixed Combination as Transition Therapy in Patients Previously on Prostaglandin Analog Monotherapy,” Journal of Clinical Ophthalmology, Vol. 6, 2012, pp. 699-706. doi:10.2147/OPTH.S30717

[39]   K. Kashiwagi, “Efficacy and Safety of Switching to Travoprost/Timolol Fixed-Combination Therapy from Latanoprost Therapy,” Japanese Journal of Ophthalmology, Vol. 56, No. 4, 2012, pp. 339-345. doi:10.1007/s10384-012-0139-2

[40]   European Glaucoma Society (EGS), “Terminology and Guidelines for Glaucoma,” Editrice Dogma S.R.L., Savona, 2008.

 
 
Top